Needham & Company Reiterates Buy on Progenics Pharma (PGNX); Anticipates Oral Relistor Approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Progenics Pharma (PGNX) Tops Q4 EPS by 4c
March 11, 2016 8:02 AM ESTProgenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.1 million versus the consensus estimate of $2.25 million.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
... MoreTrading Radar for 3/11: Genesco (GCO), Hibbett Sports (HIBB), The Buckle (BKE), Lifetime Brands (LCUT) Report
March 10, 2016 2:27 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EST
Earnings:
Century Casinos (Nasdaq:... More
